Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Neoplasm: early-phase trial registry
3 of 12 indexed Neoplasm trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,429 of 28,707 conditions by registered trial count.
12 US clinical trials · 3 currently recruiting · #1,429 of 28,707 conditions by registered trial count
Neoplasm: 12 US clinical trials tracked, 3 recruiting.
Neoplasm is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 3 of these trials.
Enrollment posture brief
Registry condition neoplasm
OPEN 3 | RECR 25% | LATE 0 | EARLY 9 | RANK #1429 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Neoplasm lists 3 open slots (25% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Neoplasm is recruiting below its size-band peers.
3 of 12 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Neoplasm research.
National Cancer Institute (NCI) accounts for 3 of 12 trials (25%). 9 distinct sponsors appear on at least one study for this condition label.
-
Typical Neoplasm enrolment sits around 100 participants.
Median target enrolment is 100 among the 12 trials that report a genuine target (sentinel values excluded). 6 of those (50%) plan for fewer than 100 participants.
-
Neoplasm research is mostly interventional.
11 interventional and 1 observational studies make up this index (91.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
12 total, page 1 of 1
A Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients
National Institutes of Health Clinical Center (CC)
NCT05909202
A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies
Compugen
NCT06759649
CARE Study: Cancer, Asian Americans, and Relationship Enrichment
Fox Chase Cancer Center
NCT06782581
Natural History of and Specimen Banking for People With Tumors of the Central Nervous System
National Cancer Institute (NCI)
NCT02851706
A Pilot Study to Investigate the Clinical Utility of the Peregrine Monte Carlo Dose Calculation System for Radiation Therapy Treatment Planning
National Cancer Institute (NCI)
NCT00026936
Trafficking of Indium-III-Labeled Cultured Immune Cells in Patients Undergoing Immunotherapy for Advanced Cancer
National Cancer Institute (NCI)
NCT00026897
Study of Karenitecin (BNP1350) to Treat Malignant Melanoma
BioNumerik Pharmaceuticals
NCT00062491
Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients With Advanced Cancer
INSYS Therapeutics
NCT00080418
Study of an Experimental New Drug, PPARγ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer
Daiichi Sankyo
NCT00408434
A Study of LY2835219 in Participants With Cancer
Eli Lilly and Company
NCT02117648
A Phase I Study of Systemic Gene Therapy With SGT-94 in Patients With Solid Tumors
SynerGene Therapeutics
NCT01517464
A Study of Galunisertib on the Immune System in Participants With Cancer
Eli Lilly and Company
NCT02304419
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Neoplasm trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Neoplasm page
12 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Neoplasm trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Neoplasm trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neoplasm condition card totals 12 registered trials; most-linked intervention Low-risk biopsy; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.